本文对７４例痛风患者进行随机对照试验，比较苯溴马龙（ｎ＝３９）与丙磺舒（ｎ＝３５）的临床疗效和安全性，结果表明，苯溴马龙组（苯组）总有效率高于丙磺舒组（丙组），分别为９７．４４％和８５．７１％和８５．７１％（ｐ＞０．０５）；治后１周血尿酸下降值苯组高于丙组，分别为２２８．４９±９１．０１和１６８．０３±１３７．４３μｍｏｌ／Ｌ（ｐ＜０．０５）；同期尿酸排泄苯组亦高于丙组。两组副反应发生率分别为２０．５１％及５４．２９％，苯组明显低于丙组（ｐ＜０．００１）。本文表明苯溴马龙较丙磺舒显效更快、副反应少、耐受性良好。 In this paper, 74 patients with gout were randomized controlled trials comparing the clinical efficacy and safety of benzbromarone (n = 39) and probenecid (n = 35). The results showed that the total effective rate Were higher than probenecid group (group C), which were 97.44% and 85.71%, respectively, and 85.71% (p> 0.05) 228.49 ± 91.01 and 168.03 ± 137.43μmol / L, respectively (p <0.05). In the same period, uric acid excretion was higher in benzene group than in group C. The incidence of side effects in both groups were 20.51% and 54.29%, respectively, in benzene group was significantly lower than that in group C (p <0.001). This article shows that benzbromarone is more effective than probenecid with less side effects and is well tolerated.